


Foretinib (GSK1363089)

Cat. No.:	OB0225WX-2394
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	5 mg; 50 mg; 200 mg; 1 g

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	Foretinib (GSK1363089) is an ATP-competitive antagonist of HGFR and VEGFR, specifically targeting c-Met and KDR with IC50 values of 0.4 nM and 0.9 nM, respectively.
--------------------	--



Synonym	EXEL-2880, XL-880, GSK089; 849217-64-7; Foretinib; XL880; GSK1363089; GSK 136308 9; XL 880; EXEL 2880; GSK-1363089; GSK-089; GSK1363089G; <i>N</i> -[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]- <i>N'</i> -(4-fluorophen yl)-1,1-cyclopropanedicarboxamide; 81FH7VK1C4; GSK-1363089G; 937176-80-2; 1- <i>N'</i> -[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1- <i>N</i> -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; 88Z; <i>n</i> -(3-fluoro-4-((6-methoxy-7-(3-(4-morpholinyl)propoxy)-4-quinolinyl)oxy)phenyl)- <i>n'</i> -(4-fluorophenyl)-1, 1-cyclopropanedicarboxamide; <i>N</i> -(3-Fluoro-4-[[6-Methoxy-7-(3-Morpholin-4-Y lpropoxy)quinolin-4-Yl]oxy}phenyl)- <i>N'</i> -(4-Fluorophenyl)cyclopropane-1,1-Dicarboxa mide; <i>N</i> -[3-fluoro-4-((6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-y l}oxy)phenyl]- <i>N'</i> -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; <i>N</i> -[3-Flu oro-4-[[6-(methoxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl] - <i>N'</i> -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; XL 880; <i>N</i> -(3-Fluoro-4 -(6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)- <i>N'</i> -(4-fluoro phenyl)cyclopropane-1,1-dicarboxamide; <i>N</i> -[3-fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl]- <i>N'</i> -(4-fluorophenyl)cyclopro pane-1,1-dicarboxamide; <i>N</i> -[3-fluoro-4-((6-methoxy-7-[(3-morpholin-4-y lpropyl)oxy]quinolin-4-yl)oxy)phenyl]- <i>N'</i> -(4-fluorophenyl)cyclopro pane-1,1-dicarboxamide; <i>N</i> -[3-fluoro-4-((6-methoxy-7-[(3-morpholin-4-y lpropyl)oxy]quinolin-4-yl)oxy)phenyl]- <i>N'</i> -(4-fluorophenyl)cyclopropane-1,1-dicarb oxamide; MFCD16038048
CAS No.	849217-64-7
Compound CID	42642645
Formula	C ₃₄ H ₃₄ F ₂ N ₄ O ₆
Formula Weight	632.65

Specification

IUPAC Name	1- <i>N'</i> -[3-Fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyp henyl]-1- <i>N</i> -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
InChI	InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
InChI Key	CXQHYVUVSFXTM-YUHFFFAOYSA-N
SMILES string	COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C 6)F)F
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Foretinib (GSK1363089) is applied in advanced cancer research as a dual MET and VEGFR2 inhibitor to investigate the disruption of hepatocyte growth factor-media ted signaling and tumor vascularization.

Library Information

Target	c-Kit; c-Met; FLT3; PDGFR; VEGFR
Receptor	c-Kit; c-Met; FLT3; PDGFR; VEGFR
Pathways	Protein tyrosine kinase
Plate Number	L6700-01
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	100 mg/mL; 158.07 mM
ALogP	4.437
HBA_Count	7
HBD_Count	2
Rotatable Bond	12